CymaBay Therapeutics Inc. (NASDAQ:CBAY) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.06, Bloomberg Earnings reports.

CymaBay Therapeutics (NASDAQ CBAY) traded down 4.17% during mid-day trading on Thursday, hitting $6.66. 505,887 shares of the stock traded hands. The stock has a 50 day moving average price of $6.44 and a 200 day moving average price of $4.33. The firm’s market cap is $191.49 million. CymaBay Therapeutics has a 12-month low of $1.15 and a 12-month high of $8.29.

In other CymaBay Therapeutics news, insider Sujal Shah acquired 10,000 shares of the stock in a transaction dated Thursday, July 20th. The shares were bought at an average price of $7.34 per share, with a total value of $73,400.00. Following the purchase, the insider now directly owns 75,891 shares of the company’s stock, valued at approximately $557,039.94. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Robert James Wills acquired 5,000 shares of the stock in a transaction dated Tuesday, August 1st. The stock was acquired at an average cost of $6.84 per share, for a total transaction of $34,200.00. Following the purchase, the director now directly owns 25,200 shares in the company, valued at $172,368. The disclosure for this purchase can be found here. Insiders bought a total of 20,000 shares of company stock worth $144,750 in the last ninety days. Corporate insiders own 15.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “CymaBay Therapeutics Inc. (NASDAQ:CBAY) Issues Quarterly Earnings Results” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/10/cymabay-therapeutics-inc-nasdaqcbay-issues-quarterly-earnings-results.html.

CBAY has been the topic of several recent analyst reports. Ifs Securities restated a “strong-buy” rating on shares of CymaBay Therapeutics in a research report on Monday, July 17th. Citigroup Inc. restated an “outperform” rating and set a $15.00 target price (up from $8.00) on shares of CymaBay Therapeutics in a research report on Thursday, July 20th. Oppenheimer Holdings, Inc. initiated coverage on shares of CymaBay Therapeutics in a research report on Friday, June 23rd. They set an “outperform” rating and a $8.00 target price on the stock. ValuEngine upgraded shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, CIBC restated an “outperform” rating and set a $15.00 target price (up from $8.00) on shares of CymaBay Therapeutics in a research report on Thursday, July 20th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $11.88.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.